Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Cash from Investing Activities (2021 - 2024)

Trinity Biotech's Cash from Investing Activities history spans 4 years, with the latest figure at -$2.7 million for Q4 2024.

  • On a quarterly basis, Cash from Investing Activities fell 207.07% to -$2.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$5.7 million, a 33.31% decrease, with the full-year FY2025 number at -$6.2 million, up 72.91% from a year prior.
  • Cash from Investing Activities hit -$2.7 million in Q4 2024 for Trinity Biotech, down from -$891000.0 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for TRIB hit a ceiling of -$1801.0 in Q2 2022 and a floor of -$2.7 million in Q4 2024.
  • Historically, Cash from Investing Activities has averaged -$1.2 million across 4 years, with a median of -$1.0 million in 2022.
  • Biggest five-year swings in Cash from Investing Activities: soared 54.02% in 2022 and later plummeted 207.07% in 2024.
  • Tracing TRIB's Cash from Investing Activities over 4 years: stood at -$2.5 million in 2021, then surged by 54.02% to -$1.1 million in 2022, then grew by 21.7% to -$891000.0 in 2023, then plummeted by 207.07% to -$2.7 million in 2024.
  • Business Quant data shows Cash from Investing Activities for TRIB at -$2.7 million in Q4 2024, -$891000.0 in Q4 2023, and -$886000.0 in Q3 2023.